Cargando…
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
Amivantamab is a bispecific antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET). In May 2021, the Food and Drug Administration gave an accelerated approval of amivantamab for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 inse...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555392/ https://www.ncbi.nlm.nih.gov/pubmed/36246734 http://dx.doi.org/10.2147/OTT.S329095 |